

### **3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples**

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) advises that the Therapeutic Goods Administration (TGA) recently registered a saliva-based protocol for collecting and testing patient samples for SARS-CoV-2 using the Company’s **3base® EasyScreen™** SARS-CoV-2 Detection Kit.

A recent study<sup>1</sup> from scientists in South Africa demonstrated that saliva swabs could be more effective than mid-turbinate nasal swabs in detecting the Omicron variant in PCR based tests, due to a higher viral RNA load in saliva than in nasal samples. This is different to other variants such as Delta that are more reliably detected from a nasal swab.

Dr. John Melki, Genetic Signatures’ CEO, commented: “Our team is driven to provide our customers with the highest quality tests and are constantly looking at ways to improve our products so they remain effective in detecting pathogens. We are pleased that this study and subsequent registration has been completed so quickly. With Omicron becoming the dominant strain of the SARS-CoV-2 virus it is likely that this new methodology will be needed to identify all cases of this new variant.”

Some of Genetic Signatures’ local customers have already adopted the protocol.

The Company announced last month that its current *EasyScreen™* SARS-CoV-2 Detection Kit could detect all known variants, including Omicron, again demonstrating the versatility of the **3base®** technology.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**  
**Chief Executive Officer**

[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)

T: +61 (0)2 9870 7580

**Peter Manley**  
**Chief Financial Officer**

[peter.manley@geneticsignatures.com](mailto:peter.manley@geneticsignatures.com)

#### ***Announcement authorised by Genetic Signatures’ Board of Directors***

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

---

<sup>1</sup> Marais G. (2021). Saliva swabs are the preferred sample for Omicron detection. *medRxiv*. <https://www.medrxiv.org/content/10.1101/2021.12.22.21268246v1>